Akriveia Therapeutics
Thousand Oaks
California
United States
Website: http://www.akriveiatx.com/
Email: nfo@akriveiatx.com
About Akriveia Therapeutics
Akriveia Therapeutics is discovering and developing the next generation of cancer immunotherapies. Akriveia’s new agents offer the promise of a safer and more efficacious approach to harness a patient’s own immune system to attack cancer.About our name: “Akriveia” is a Greek word meaning “Precision” or “Accuracy” and reflects our mission to develop best-in-class immunotherapeutics through the precise targeting of our therapeutics to tumors.
YEAR FOUNDED:
2015
LEADERSHIP:
CEO: Simon Tomlinson
CSO: C. Glenn Begley
Co-Founder and Member of Scientific Advisory Board: Uli Rodeck
Co-Founder and Member of Scientific Advisory Board: John C. Williams
Vice President, Discovery and Preclinical Development: Margaret Karow
JOBS:
Please click here for Akriveia's job opportunities.
3 articles about Akriveia Therapeutics
-
Akriveia Therapeutics' Aklusion Platform for Tumor-Targeting Cancer Immunotherapies to be Featured in Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 32nd Annual Meeting
11/7/2017
The poster's authors include scientists from the laboratories of Professor John Williams of the Beckman Research Institute at the City of Hope and Professor Ulrich Rodeck at Thomas Jefferson University, along with Dr. Margaret Karow, Senior Vice President of Drug Discovery and Preclinical Development at Akriveia Therapeutics.
-
Akriveia Therapeutics Announces Key Additions To Its Leadership Team
11/11/2016
-
Akriveia Therapeutics Announces Its Recent Series A Investment By F-Prime Capital Partners
10/12/2016